A Agrawal

A Guarino

A Kassinen

A Seth

B Coulie

Beom-Gi Hong

Beom-Joon Lee

Bongha Ryu

C Wang

CM Chapman

D Hollander

DA Drossman

DA Lemberg

E Malinen

EO Petrof

GF Longstreth

HJ Kim

HL Smart

I Bjarnason

Inkwon Yeo

J Jailwala

J Mättö

Jae-Woo Park

JH Han

Jin-Moo Lee

Jinsung Kim

JM Si

K Kajander

K Li

KW Ryu

L O'Mahony

LI Kang

M Camilleri

N Hoveyda

Q Zhou

RD Rolfe

S Ménard

S Pathmakanthan

Seok-Jae Ko

SJ Lewis

SP Dunlop

V Di Leo

WK Leung

YB Kim

YC Xie

YH He

Trials

English

PubMed

Abstract
          
            Background
            Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by abdominal pain and change of bowel habits without organic disease. Many patients seek alternative IBS treatments because of the limitations of conventional treatments. Gwakhyangjeonggisan (GJS), a herbal formula, has long been used for alleviating diarrhea-predominant IBS (D-IBS) in traditional medicine. Duolac7S, which comprises 7 bacterial species as probiotics, has been frequently used for D-IBS. Although GJS and Duolac7S have been administered simultaneously in many D-IBS patients, no study has investigated the effects of GJS and Duolac7S combination therapy on D-IBS.
          
          
            Methods/Design
            The current trial is a randomized, double-blinded, placebo-controlled, 4-arm study. After a 2-week run-in period, 60 patients with D-IBS will be randomly assigned to one of the 4 combination groups consisting of GJS (water extract granules, 3 g/pack, 3 times a day) with Duolac7S (powder form, 1 capsule, 2 times a day) or their placebos and followed up for 2 weeks. The assigned treatments will last for 8 weeks. The primary outcomes are adequate relief of IBS pain and discomfort and the proportion of responders (on a weekly basis). The secondary outcomes are visual analog scale for IBS symptoms (on a daily basis), quality of life (at 0, 8, and 10 weeks), intestinal permeability, and composition of intestinal microbiota (at 0 and 8 weeks).
          
          
            Discussion
            The present study is designed to examine the safety and efficacy of GJS and Duolac7S combination therapy on D-IBS. Our study provides the clinical evidence of a new therapeutic strategy for D-IBS.
          
          
            Trial registration
            ClinicalTrials.gov NCT01342718.
          </jats:sec

Crossref

Effect of herbal extract granules combined with probiotic mixture on irritable bowel syndrome with diarrhea: study protocol for a randomized controlled trial

Springer - Publisher Connector

A: The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology

Alternative medicine consultations and remedies in patients with the irritable bowel syndrome. Gut

AR: A randomized controlled trial of a porbiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther

AR: A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil

Bangdiwala SI: Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire.

BY: Effects on Koakhyangieonggisan and Gamikoahyangieonggisan on the digestive and anti-allergic function.

Cedarbaum JM: Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology

CJ: Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon.

Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther

Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome-a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol

Day AS: Probiotics in paediatric gastrointestinal diseases.

Determination of liquiritin, naringin, hesperidin, thymol, imperatorin, honokiol, isoimperatorin, and magnolol in the traditional Chinese medicinal preparation Huoxiang-zhengqi liquid using high-performance liquid chromatography. Yakugaku Zasshi

DW: Experimental comparative studies on the effects of Kwakhyangjeonggisan and Souminkwakhyang-jeonggisan. KyungHee Orient Med Coll J

EG: A clinical report of chronic diarrhea treated with GwakHyang-JungGiSan. Korean J Orient Int Med

Glasziou P: A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome.

GN: Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain

Heaton KW: Stool form scale as a useful guide to intestinal transit time.

Herbal formula and lactic acid bacteria. [http://www.akomnews.com/ subpage/search_detail.php?code=A001&uid=53825&page=/subpage/search.

I: Health benefits of probiotics: are mixtures more effective than single strains?

Intestinal permeability, leaky gut and intestinal disorders. Curr Gastroenterol Rep

Intestinal permeability: an overview. Gastroenterology

Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology

Is there a role for probiotics in irritable bowel syndrome? Dig Liver Dis

Korean Food and Drug Administration.

Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut

Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology

Lo Vecchio A, Canani RB: Probiotics as prevention and treatment for diarrhea. Curr Opin Gastroenterol

Lu AP: Effects of huoxiangzhengqi liquid on enteric mucosal immune responses in mice with Bacillus dysenteriae and Salmonella typhimurium induced diarrhea.

Nishino N: Presence of sourdough lactic acid bacteria in commercial total mixed ration silage as revealed by denaturing gradient gel electrophoresis analysis. Lett Appl Microbiol

Palva A: Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome.

Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med

Probiotics and gastrointestinal disease: clinical evidence and basic science. Antiinflamm Antiallergy Agents Med Chem

Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy.

RC: Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes.

RC: Functional bowel disorders. Gastroenterology

RK: Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism.

SJ: Intestinal microecology and quality of life in irritable bowel syndrome patients.

Sturniolo GC: Lactulose/mannitol test has high efficacy for excluding organic causes of chronic diarrhea.

Sung JJ: Treatment of diarrhea predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial.

Tang F: Experimental study on protecting intestinal barrier function of Huoxiang Zhengqi soft capsule. Zhongguo Zhong Yao Za Zhi

The role of probiotic cultures in the control of gastrointestinal health.

Whorwell PJ: Irritable bowel syndrome: diagnosis and management. BMJ

YY: Mechanism of effect of Huoxiang Zhengqi liquid on the spontaneous contraction of colonic muscle from mice. Chin J Exp Trad Med Formulae

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3198690

Effect of herbal extract granules combined with probiotic mixture on irritable bowel syndrome with diarrhea: study protocol for a randomized controlled trial

Abstract

Similar works

Full text

Available Versions

Crossref

Springer - Publisher Connector